Brucella abortus Proteins for Diagnostic Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for brucellosis lack reliability due to low specificity and sensitivity, and existing approaches for detecting Brucella abortus infections in animals are not consistently effective, particularly in differentiating between naturally infected and vaccinated animals, and do not adequately address the challenge of wildlife reservoirs like elk in the Greater Yellowstone Area.
Innovation Solution
The use of In Vivo-Induced Antigen Technology (IVIAT) to identify Brucella abortus antigens expressed during infection, specifically targeting malate dehydrogenase (Mdh), D15, and AfuA proteins, which are immunologically specific and can differentiate between naturally infected and vaccinated animals, and the development of compositions and kits for detection and prevention of Brucella abortus infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional Brucella diagnostic methods are used, then the diagnostic process is simple, but the specificity and sensitivity are insufficient
Solution Approach 1:
The patent changes the diagnostic parameters by switching from traditional agglutination tests to ELISA-based serologic diagnosis using recombinant proteins (Mdh, D15, AfuA) as antigens. This parameter change enables differentiation between vaccinated and naturally infected animals through specific antibody response patterns, thereby improving diagnostic accuracy without excessive complexity
Solution Approach 2:
The patent introduces recombinant proteins (Mdh, D15, AfuA) as intermediary antigens in the diagnostic process. These intermediaries enable more specific detection of Brucella infections by eliciting distinct antibody responses that can differentiate between vaccination and natural infection, improving measurement precision while maintaining operational feasibility
2Measurement precision
If LPS-based serologic diagnosis is used, then sensitivity is improved, but geographic areas of false positive reactions reduce specificity
Solution Approach 1:
The patent applies local quality by using different recombinant protein antigens (Mdh, D15, AfuA) with distinct immunogenic properties in different diagnostic contexts. These localized antigen selections enable specific detection patterns that maintain high sensitivity while improving specificity by avoiding the geographic false positive issues associated with LPS-based methods
Solution Approach 2:
The patent segments the diagnostic approach by using multiple discrete recombinant protein antigens instead of a single LPS target. This segmentation allows for composite diagnostic criteria that can distinguish true positives from false positives, thereby maintaining sensitivity while improving specificity through multi-parameter assessment
3Reliability
If Signature Tagged Mutagenesis is used to identify virulence genes, then in vivo survival genes are identified, but immunogenic gene products are not detected and the method is sensitive to experimental variables
Solution Approach 1:
The patent inverts the STM approach by using IVIAT (In Vivo-Induced Antigen Technology) instead of negative selection. This inversion allows simultaneous identification of both virulence genes and immunogenic gene products by detecting antibodies against in vivo-expressed antigens, thereby resolving the contradiction between identifying survival genes and detecting immunogenic products
4Measurement precision
If differentiation between naturally infected and vaccinated animals is required, then diagnostic accuracy improves, but existing methods cannot reliably achieve this differentiation
Solution Approach 1:
The patent changes the diagnostic parameters by using recombinant proteins (Mdh, D15, AfuA) that elicit different antibody responses in vaccinated versus naturally infected animals. This parameter change enables reliable differentiation through specific serologic patterns, achieving both improved measurement precision and reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IVIAT effectively identifies serologic markers for brucellosis in elk and domestic livestock, providing a reliable method for distinguishing between naturally infected and vaccinated animals, and offers potential vaccine candidates that can induce protective immune responses, thereby enhancing diagnostic accuracy and infection prevention.
Implementation Method 1
detecting the presence of at least one antibody immunologically specific for at least one Brucella abortus protein, wherein the presence of antibodies to the Brucella abortus protein indicates a Brucella abortus infection in the animal
Data Source
AI summary
Compositions and methods for the diagnosis and prevention of B. abortus infection are provided.